Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
21 September 2024
| Name: | BENITEC LIMITED (BLT) (This company subsequently changed its name and is now BENITEC BIOPHARMA LIMITED. You should refer to that name for Status.) | ||||||
| Date of Listing: | 17 February 1997 | ||||||
| Subsequent Names: |
| ||||||
| Former Names: |
|
Stock Exchange Status:
This company subsequently changed its name and is now BENITEC BIOPHARMA LIMITED. You should refer to that name for Stock Exchange Status.Legal Status:
This company subsequently changed its name and is now BENITEC BIOPHARMA LIMITED. You should refer to that name for Legal Status.Capital Gains Tax (CGT) Status:
This company subsequently changed its name and is now BENITEC BIOPHARMA LIMITED. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| BENITEC BIOPHARMA LIMITED | 25/11/2011 | |
| BENITEC LIMITED | 30/04/2002 | 25/11/2011 |
| QUEENSLAND OPALS NL | 30/04/2002 |
REGISTRY:
Computershare Brisbane
Level 1, 200 Mary Street Brisbane QLD 4000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 7 3229 9860
RegistryWebsite RegistryEmail
name changed to Benitec Biopharma Limited | 25/11/2011 |
the quoted options (ASX Code BLTOA) of Benitec Limited (the "Company") will be suspended from quotation at the close of trading today, Friday 25 March 2011, in accordance with listing rule 17.3.3 and Appendix 6A, pending expiry of the options on 3 April 2011. For further details please see the Company's Option Expiry Notice released on 3 March 2011 | 25/03/2011 |
the suspension of trading in the securities of Benitec Limited (the "Company") will be lifted immediately, following receipt of an announcement in relation to a Non-Final Office Action from the US Patents and Trademarks Office | 21/04/2008 |
securities suspended from quotation pending an announcement | 16/04/2008 |
shares reinstated to quotation | 24/10/2006 |
the board advises that the final audited financial accounts for 2005 2006 and Directors report due to be submitted to the ASX will be further delayed - it expects to have resolution later this week | 17/10/2006 |
the company has secured a $1 million unsecured loan from a sophisticated Australian investor - the investor Dr Chris Bremner will provide 3 installments over 12 months and the first installment of $350,000 was received overnight - the Board has agreed to allow Dr Bremner to convert the loan into shares | 17/10/2006 |
company has secured upfront payments, a scale of milestone payments and a potential future royalty stream by licensing its gene silencing technology for treating Hepatitis C - Benitec will also receive a 5 percent equity stake in California-based Tacere Therapeutics, Inc | 11/10/2006 |
company advises that the final audited financial accounts for 2005 / 2006 and Directors report due to be submitted to the ASX will be delayed until at least late next week | 06/10/2006 |
securities suspended from quotation because of failure to lodge full year accounts for the period to 30 June 2006 | 02/10/2006 |
name changed from Queensland Opals NL | 30/04/2002 |
name changed to Benitec Biopharma Limited | 25/11/2011 |
the quoted options (ASX Code BLTOA) of Benitec Limited (the "Company") will be suspended from quotation at the close of trading today, Friday 25 March 2011, in accordance with listing rule 17.3.3 and Appendix 6A, pending expiry of the options on 3 April 2011. For further details please see the Company's Option Expiry Notice released on 3 March 2011 | 25/03/2011 |
the suspension of trading in the securities of Benitec Limited (the "Company") will be lifted immediately, following receipt of an announcement in relation to a Non-Final Office Action from the US Patents and Trademarks Office | 21/04/2008 |
securities suspended from quotation pending an announcement | 16/04/2008 |
shares reinstated to quotation | 24/10/2006 |
the board advises that the final audited financial accounts for 2005 2006 and Directors report due to be submitted to the ASX will be further delayed - it expects to have resolution later this week | 17/10/2006 |
the company has secured a $1 million unsecured loan from a sophisticated Australian investor - the investor Dr Chris Bremner will provide 3 installments over 12 months and the first installment of $350,000 was received overnight - the Board has agreed to allow Dr Bremner to convert the loan into shares | 17/10/2006 |
company has secured upfront payments, a scale of milestone payments and a potential future royalty stream by licensing its gene silencing technology for treating Hepatitis C - Benitec will also receive a 5 percent equity stake in California-based Tacere Therapeutics, Inc | 11/10/2006 |
company advises that the final audited financial accounts for 2005 / 2006 and Directors report due to be submitted to the ASX will be delayed until at least late next week | 06/10/2006 |
securities suspended from quotation because of failure to lodge full year accounts for the period to 30 June 2006 | 02/10/2006 |
name changed from Queensland Opals NL | 30/04/2002 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 18/11/2011 | Melvyn Bridges | On market | 1,850,000 | $0.016 | $29,926 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Peter Francis | Non Exec Chairman | 08/02/2006 |
| Peter French | CEO | 04/06/2010 |
| Greg West | CFO, Company Secretary | 01/08/2011 |
| Melvyn Bridges | Executive Director | 12/10/2007 |
| John Chiplin | Executive Director | 01/02/2010 |
| Iain Ross | Director | 01/06/2010 |
| Michael Dalling | Director |
Date of first appointment, title may have changed.
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
